By Jason Derry —

On Wednesday, Roche announced that it would acquire BioVeris Corporation for about $600 million.  The purchase of BioVeris will allow Roche to expand its immunochemistry business into the life science research and development, drug discovery, and clinical research areas.

Roche’s announcement that it would be acquiring BioVeris came two days after the company announced that it had acquired Therapeutic Human Polyclonals, Inc. for $56.5 million.  Therapeutic Human Polyclonals
has developed transgenic rabbits in which human polyclonal antibodies
can be developed, allowing Roche to expand its therapeutic antibody
discovery and development program to include human polyclonal
antibodies.